Results of ovary tumor treatment with abdominally administered (198)Au evaluated on the basis of long term follow up

• Published in: Pathology oncology research Vol. 8; no. 1; p. 54
• Main Authors: Patyánik, Mihály, Mayer, Arpád, Polgár, István
• Format: Journal Article
• Language: English
• Published: Switzerland 2002
• Subjects: Abdominal Pain - etiology; Aged; Aged, 80 and over; Diabetes Mellitus - etiology; Enteritis - etiology; Female; Follow-Up Studies; Gold Radioisotopes - administration & dosage; Gold Radioisotopes - adverse effects; Gold Radioisotopes - therapeutic use; Humans; Infusions, Parenteral; Intestinal Obstruction - etiology; Intestinal Perforation - etiology; Middle Aged; Ovarian Neoplasms - mortality; Ovarian Neoplasms - radiotherapy; Time Factors; Ulcer - etiology
• ISSN: 1219-4956
• DOI: 10.1007/BF03033702

In the period between 1959 and 1980 165 patients previously operated with ovarian tumor were treated by intraperitoneally administered (198)Au in the Oncoradiological Centre of the Uzsoki Hospital. The stage distribution of the 158 patients with common epithelial histology was as it follows: Stage I/A 31; Stage I/B 9; Stage I/C 59; Stage II/A 19; Stage II/B 11; Stage II/C 7, Stage III/A 22. The five year survival result is the next: Stage I/A 90%; Stage I/B 78%; Stage I/C 58%; Stage II/A 26%; Stage II/B 27%; Stage II/C 14%; Stage III/A 18%. From the other 7 patients six had sex cord tumor and one lipid cell tumor. The number of the side effects is in good agreement with the data in literature. The use of (198)Au for intraperitoneal treatment of ovary tumors is not contemporary today because of gamma radiation of radiogold, but intraperitoneal radiation treatment should not be forgotten.